Bio-Techne (NASDAQ:TECH – Get Free Report) is expected to announce its Q1 2027 results before the market opens on Wednesday, November 4th. Analysts expect the company to post earnings of $0.44 per share and revenue of $292.60 million for the quarter. Individuals may review the information on the company’s upcoming Q1 2027 earnings report for the latest details on the call scheduled for Wednesday, November 4, 2026 at 9:00 AM ET.
Bio-Techne (NASDAQ:TECH – Get Free Report) last issued its earnings results on Wednesday, August 12th. The biotechnology company reported $0.52 EPS for the quarter, meeting analysts’ consensus estimates of $0.52. The company had revenue of $321.19 million during the quarter, compared to analyst estimates of $314.63 million. The business’s revenue was up 1.3% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.53 earnings per share. On average, analysts expect Bio-Techne to post $1.70 EPS for the current fiscal year and $1.91 EPS for the next fiscal year.
Bio-Techne Price Performance
Shares of NASDAQ TECH opened at $72.60 on Wednesday. Bio-Techne has a 12-month low of $43.19 and a 12-month high of $72.75. The stock’s 50 day simple moving average is $72.43 and its 200 day simple moving average is $63.17.
Bio-Techne Increases Dividend
The company also recently disclosed a quarterly dividend, which was paid on Friday, September 4th. Investors of record on Monday, August 24th were issued a $0.65 dividend. This is a boost from Bio-Techne’s previous quarterly dividend of $0.08. The ex-dividend date of this dividend was Monday, August 24th. This represents a $2.60 dividend on an annualized basis and a dividend yield of 3.6%.
Analysts Set New Price Targets
Several equities research analysts have commented on TECH shares. Royal Bank Of Canada lowered shares of Bio-Techne from an “outperform” rating to a “sector perform” rating and raised their price target for the company from $62.00 to $73.00 in a research note on Thursday, July 9th. Wells Fargo & Company lowered Bio-Techne from an “overweight” rating to an “equal weight” rating and increased their price objective for the stock from $62.00 to $73.00 in a report on Thursday, August 13th. Zacks Research upgraded Bio-Techne from a “strong sell” rating to a “hold” rating in a research report on Tuesday, August 25th. Weiss Ratings upgraded Bio-Techne from a “hold (c-)” rating to a “hold (c)” rating in a research report on Tuesday, August 25th. Finally, Benchmark reaffirmed a “hold” rating on shares of Bio-Techne in a research note on Wednesday, August 19th. One research analyst has rated the stock with a Buy rating, fifteen have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $68.92.
Get Our Latest Analysis on Bio-Techne
About Bio-Techne
Bio-Techne Corporation is a life sciences company that develops and supplies research and diagnostic products for biotechnology, pharmaceutical, academic, clinical and other laboratory customers. The company supports biological research, drug discovery and development, and diagnostic testing through a portfolio of reagents, instruments and analytical technologies.
Its products include proteins, antibodies, immunoassays, flow cytometry reagents, molecular biology tools and cell culture materials.
Read More
- Five stocks we like better than Bio-Techne
- These 3 New ETFs Are Turning Heads—Are They Worth Buying?
- Coca-Cola Stock Is Everything AI Isn’t—And That’s Its Biggest Strength
- Apple’s Foldable iPhone Sold Out in Minutes, But Wall Street Has Questions
- Netflix Is Making Big Changes, But Can It Fix What’s Really Hurting Growth?
Receive News & Ratings for Bio-Techne Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Techne and related companies with MarketBeat.com's FREE daily email newsletter.
